Articles On Neuren Pharmaceuticals (ASX:NEU)

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a pleasant end to the trading week this Friday, clawing back some of the week's lost ground to finish in the green. By the time the closing bell rang, t...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares were out of form on Tuesday after getting caught up in the market selloff. The ASX 200 stock ended the day 6% lower at $11.40. This leaves the pharmaceutical company's shares trading within sight...

The Australian share market is a sea of red again on Tuesday. Investors have been hitting the sell button in a panic following a selloff on Wall Street caused by US recession concerns. While the market volatility can be hard to stomach, his...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

ASX investors finally caught another break this Thursday, with the S&P/ASX 200 Index (ASX: XJO) rising for only its second session in the past nine trading days. By the time the markets closed...

Highlights: Karoon Energy strengthens its operational framework with an asset acquisition for its Brazil-based project. Qantas announces a dividend reinstatement, reflecting financial recovery in the aviation sector. Fluctuations...

Good afternoon and welcome to the Thursday edition of Market Close, I’m Jonathon Davidson. It was a somewhat happier day as Australian icon Qantas paid its first dividend in years and household name Coles proved to be consistently growing....

The S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain on Thursday. In afternoon trade, the benchmark index is up 0.4% to 8,272 points. Four ASX shares that are rising more than most today are listed below. Here's why the...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...

The S&P/ASX 200 Index (ASX: XJO) had a wild start to the week's trading this Monday. Overcoming a big opening loss, it finished 0.14% higher by the closing bell, breaking last week's five-day...

The S&P/ASX 200 Index (ASX: XJO) has fought back from a poor start and is down in afternoon trade. At the time of writing, the benchmark index is down slightly to 8,289.8 points. Four ASX shares that are not letting that hold them bac...

The market may be heading lower today but that hasn't stopped two ASX 200 pharmaceutical shares from charging higher. Let's find out what big news out of the United States is giving them a big boost today. Here's what you need to know: Neu...

Neuren Pharmaceuticals (ASX: NEU) has been granted the chance to talk to the U.S. Food and Drug Administration (FDA) about some of the positive indicators that may be expected from its upcoming Phase 3 clinical trial program for a drug to t...

It was a fantastic day for the S&P/ASX 200 Index (ASX: XJO) and many ASX 200 shares this Wednesday, with investors throwing off the negativity that spoiled yesterday's session By the time the...

Highlights: Fisher & Paykel Healthcare (ASX:FPH) faces new tariffs but is adapting with strategic measures. Orthocell (ASX:OCC) is progressing with regulatory approvals in multiple markets. Life-sciences...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

ASX health stocks up 0.6% over past week, while the broader market rises 1%  EBR Systems is up ~58% in a month, briefly hitting Morgans price target of $1.76 Morgans drops rating of Nanosonics to a hold despite strong H1 FY25 Healthcare a...

The S&P/ASX 200 Index (ASX: XJO) ended its trading week on a low this Friday, banking a loss after a wild trading session. After spending some of the day comfortably in green territory, invest...

Pic via Getty ImagesRadiopharmaceuticals company Telix reports sustained revenue growth in Q4 FY24 ASX health stocks fall about 2.8% over past week Neuren’s partner Acadia submits marketing authorisation application in Europe for trofine...

It was a jubilant Thursday session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, giving investors some much-needed relief. After a shaky week, the ASX 200 wasn't holding back...

Highlights ASX climbs 1.4% after robust jobs data. Commonwealth Bank (CBA) gains 2.7%. Neuren Pharmaceuticals (NEU) sees biggest single-session rise of 9%.   The Australian stock market rallied on Thursday, with the S&P/ASX 2...

The ASX200 closed down 0.22% at 8,213 points. The local bourse gave up early gains and slipped into the red in afternoon trade, and did not return to positive territory. The Discretionary sector was the best performer, up 0.2%, follow...

After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index (ASX: XJO) this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat...

The S&P/ASX 200 Index (ASX: XJO) is running out of steam and fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up slightly to 8,230.9 points. Four ASX shares that are weighing on the market today...

Are you a fan of growth stocks? If you are, then it could be worth looking at the two ASX 200 growth shares listed below. That's because they have been named as buys by brokers and tipped to rise strongly from current levels. Here's what th...

It was another pleasant day for the S&P/ASX 200 Index (ASX: XJO) and Australian investors this Wednesday. After tentatively rising all week, investors stepped on the buying pedal this hump day...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Do you have $10,000 to invest into ASX 200 shares in January? If you do, then it could be worth considering the two shares in this article. Let's see why they could be great options for investors this month: Neuren Pharmaceuticals Ltd (AS...

Highlights - The ASX 200 index closed 0.92% lower during the final session of 2024.  - Nine out of eleven sectors recorded declines, led by gold and consumer-focused stocks.  - Energy stocks were the top performers as crude prices sup...

Morgans sees opportunities among several ASX healthcare stocks in 2025 Broker looking at stocks with near-term catalysts or sold down with good entry opportunities Morgans’ Christmas stocking has mix of up-and-comers alongside mature names...

Looking for growth stocks to buy in 2025? If you are, then it could be worth looking at the three ASX 200 growth shares listed below. They have been named as buys by brokers and tipped to rise strongly from current levels. Here's what they...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

If you are fortunate enough to have $5,000 spare to invest into ASX 200 shares, then read on. That's because listed below are three shares that analysts are tipping as top buys for the year ahead. Here's what you need to know about them: D...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Index (ASX: XJO) suffered another fall this Wednesday, helping to cement what has been a fairly rough week for the Australian market. After a brief foray into positive ter...

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

Last Friday, the Fat Tail Investment Research crew gathered in our South Melbourne office for our annual Christmas party. We enjoyed light conversations, karaoke singing and thank-you speeches over sushi, fried chicken, snacks, beers and o...

It was another fantastic day for the S&P/ASX 200 Index (ASX: XJO) this Tuesday, with the index hitting its latest new all-time high. The ASX 200 added 0.56% by the close of today's session, le...

The intrigue of ASX growth shares enthrals many investors. Often, stocks in this category catch headlines and see their shares bid up to high prices. Qualifying these companies for 'growth' is the growth in their historical and future...

Highlights  ASX200 falls 0.57% after touching a record high near 8,400 points.    Health Care sector posts modest gains despite broad losses.   Small-cap stocks show strong individual performances. The Australian Securities Exchan...

ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7%  Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate...

The best ASX shares in terms of share price gains since the US election make for interesting reading. Based on data from S & P Global Market Intelligence, here are the top 10 ASX 200 shares. Best-performing ASX 200 shares since...

The S&P/ASX 200 Index (ASX: XJO) managed to snap the three-day losing streak it had been on this week to push higher today. After falling all week, ASX investors appeared to decide enou...

Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, whic...

The S&P/ASX 200 Index (ASX: XJO) endured another rough day of trading this Tuesday, making the trading week so far a bit of a downer. After getting a walkback from investors yesterday, th...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.5% to 8,223.4 points. Four ASX shares that are not letting that hold them back today ar...